Complement factor B Bb fragment
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric(1) Consistent with protein copy count | Chain A; UniProt 268–764 | Fragment:COMPLEMENT FACTOR B BB FRAGMENT Mutation:F428C, N435C, C267V | IOD IODIDE ION × 2 NA SODIUM ION × 7 MG MAGNESIUM ION × 1 GBS 4-carbamimidamidobenzoic acid × 1 | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION, HANGING DROP;298 K;PEGMME 2000, NaI, VAPOR DIFFUSION, HANGING DROP, temperature 298K | Resolution 2.30 Å R-free 0.245 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 1RTK | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1DLE FACTOR B SERINE PROTEASE DOMAIN Deposited 1999-12-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
470–764(295 aa)
Fragment:SERINE PROTEASE DOMAIN
Chain B
470–764(295 aa)
Fragment:SERINE PROTEASE DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;298 K;PEG-1000, MES, TRIS, SODIUM CHLORIDE, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å R-free 0.249 |
| 1Q0P A domain of Factor B Deposited 2003-07-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
254–476(223 aa)
Fragment:sequence database residues 254-476
|
Mutation:C267S | MN MANGANESE (II) ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;30% Jeffamine, 0.05M Ceseium Chloride, 0.1M MES, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.80 Å R-free 0.259 |
| 1RRK Crystal Structure Analysis of the Bb segment of Factor B Deposited 2003-12-08 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
243–764(522 aa)
Fragment:COMPLEMENT FACTOR B BB FRAGMENT
|
Mutation:F428C, N435C, C267V | IOD IODIDE ION × 2 NA SODIUM ION × 7 CO COBALT (II) ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298 K;PEGMME 2000, NaI, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.00 Å R-free 0.245 |
| 1RS0 Crystal Structure Analysis of the Bb segment of Factor B complexed with Di-isopropyl-phosphate (DIP) Deposited 2003-12-09 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
268–764(497 aa)
Fragment:COMPLEMENT FACTOR B BB FRAGMENT
|
Mutation:F428C, N435C, C267V | IOD IODIDE ION × 2 NA SODIUM ION × 7 MG MAGNESIUM ION × 1 DFP DIISOPROPYL PHOSPHONATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298 K;PEGMME 2000, NaI, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.60 Å R-free 0.251 |
| 2OK5 Human Complement factor B Deposited 2007-01-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
26–764(739 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 GOL GLYCEROL × 13 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;12% PEG 1500, 0.02 M Malic acid, 0.04 M MES, 0.04 M TRIS, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.241 |
| 2WIN C3 convertase (C3bBb) stabilized by SCIN Deposited 2009-05-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 8 PDB declaration: octameric |
Chain J
260–764(505 aa)
Fragment:COMPLEMENT FACTOR B BB FRAGMENT, RESIDUES 260-764
Chain L
260–764(505 aa)
Fragment:COMPLEMENT FACTOR B BB FRAGMENT, RESIDUES 260-764
|
Not recorded | MAN alpha-D-mannopyranose × 1 BMA beta-D-mannopyranose × 1 MG MAGNESIUM ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5;75 MM SODIUM/POTASSIUM TARTRATE, 8.0% PEG 3350, 50 MM BIS-TRIS PROPANE, PH 6.5
|
Resolution 3.90 Å R-free 0.268 |
| 2WIN C3 convertase (C3bBb) stabilized by SCIN Deposited 2009-05-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer;Protein × 8 PDB declaration: octameric |
Chain I
260–764(505 aa)
Fragment:COMPLEMENT FACTOR B BB FRAGMENT, RESIDUES 260-764
Chain K
260–764(505 aa)
Fragment:COMPLEMENT FACTOR B BB FRAGMENT, RESIDUES 260-764
|
Not recorded | BMA beta-D-mannopyranose × 1 MG MAGNESIUM ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5;75 MM SODIUM/POTASSIUM TARTRATE, 8.0% PEG 3350, 50 MM BIS-TRIS PROPANE, PH 6.5
|
Resolution 3.90 Å R-free 0.268 |
| 2XWB Crystal Structure of Complement C3b in complex with Factors B and D Deposited 2010-11-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain F
35–764(730 aa)
Fragment:RESIDUES 35-764
|
Mutation:YES | MG MAGNESIUM ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.7;PH 7.7
|
Resolution 3.49 Å R-free 0.244 |
| 2XWB Crystal Structure of Complement C3b in complex with Factors B and D Deposited 2010-11-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain H
35–764(730 aa)
Fragment:RESIDUES 35-764
|
Mutation:YES | MG MAGNESIUM ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.7;PH 7.7
|
Resolution 3.49 Å R-free 0.244 |
| 2XWB Crystal Structure of Complement C3b in complex with Factors B and D Deposited 2010-11-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain H
35–764(730 aa)
Fragment:RESIDUES 35-764
|
Mutation:YES | MG MAGNESIUM ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.7;PH 7.7
|
Resolution 3.49 Å R-free 0.244 |
| 2XWB Crystal Structure of Complement C3b in complex with Factors B and D Deposited 2010-11-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain F
35–764(730 aa)
Fragment:RESIDUES 35-764
|
Mutation:YES | MG MAGNESIUM ION × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.7;PH 7.7
|
Resolution 3.49 Å R-free 0.244 |
| 2XWJ Crystal Structure of Complement C3b in Complex with Factor B Deposited 2010-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain I
26–764(739 aa)
Fragment:COMPLEMENT FACTOR B
|
Mutation:YES | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 NI NICKEL (II) ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4;pH 4.0
|
Resolution 4.00 Å R-free 0.281 |
| 2XWJ Crystal Structure of Complement C3b in Complex with Factor B Deposited 2010-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain J
26–764(739 aa)
Fragment:COMPLEMENT FACTOR B
|
Mutation:YES | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 NI NICKEL (II) ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4;pH 4.0
|
Resolution 4.00 Å R-free 0.281 |
| 2XWJ Crystal Structure of Complement C3b in Complex with Factor B Deposited 2010-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain L
26–764(739 aa)
Fragment:COMPLEMENT FACTOR B
|
Mutation:YES | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 NI NICKEL (II) ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4;pH 4.0
|
Resolution 4.00 Å R-free 0.281 |
| 2XWJ Crystal Structure of Complement C3b in Complex with Factor B Deposited 2010-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain K
26–764(739 aa)
Fragment:COMPLEMENT FACTOR B
|
Mutation:YES | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 NI NICKEL (II) ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4;pH 4.0
|
Resolution 4.00 Å R-free 0.281 |
| 3HRZ Cobra Venom Factor (CVF) in complex with human factor B Deposited 2009-06-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain D
26–764(739 aa)
Fragment:residues 26-764
|
Mutation:D279G,N285D | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 MG MAGNESIUM ION × 2 K POTASSIUM ION × 1 P6G HEXAETHYLENE GLYCOL × 2 PO4 PHOSPHATE ION × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;PEG 3350, PEG 400, Na/K Phosphate, Bis-Tris propane, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.20 Å R-free 0.226 |
| 3HS0 Cobra Venom Factor (CVF) in complex with human factor B Deposited 2009-06-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain I
26–764(739 aa)
Fragment:residues 26-764
|
Mutation:D279G,N285D | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 9;291 K;PEG 1500, 2,3 butanediol, malic acid 2-(N-morpholino)ethanesulfonic acid tris (hydroxymethyl)aminomethane buffer (MMT), pH 9.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 3.00 Å R-free 0.243 |
| 3HS0 Cobra Venom Factor (CVF) in complex with human factor B Deposited 2009-06-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain D
26–764(739 aa)
Fragment:residues 26-764
|
Mutation:D279G,N285D | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 9;291 K;PEG 1500, 2,3 butanediol, malic acid 2-(N-morpholino)ethanesulfonic acid tris (hydroxymethyl)aminomethane buffer (MMT), pH 9.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 3.00 Å R-free 0.243 |
| 3HS0 Cobra Venom Factor (CVF) in complex with human factor B Deposited 2009-06-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Other combination Heteromer;Protein × 8 PDB declaration: octameric |
Chain D
26–764(739 aa)
Fragment:residues 26-764
Chain I
26–764(739 aa)
Fragment:residues 26-764
|
Mutation:D279G,N285D Mutation:D279G,N285D | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 9;291 K;PEG 1500, 2,3 butanediol, malic acid 2-(N-morpholino)ethanesulfonic acid tris (hydroxymethyl)aminomethane buffer (MMT), pH 9.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 3.00 Å R-free 0.243 |
| 6QSW Complement factor B protease domain in complex with the reversible inhibitor N-(2-bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine. Deposited 2019-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain AAA
474–764(291 aa)
|
Not recorded | SO4 SULFATE ION × 3 JGT ~{N}-(2-bromanyl-4-methyl-naphthalen-1-yl)-4,5-dihydro-1~{H}-imidazol-2-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;2.0 M ammonium sulfate, 0.1 M sodium acetate (pH 4.6), 2 mM inhibitor
|
Resolution 1.64 Å R-free 0.188 |
| 6QSW Complement factor B protease domain in complex with the reversible inhibitor N-(2-bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine. Deposited 2019-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain BBB
474–764(291 aa)
|
Not recorded | SO4 SULFATE ION × 4 JGT ~{N}-(2-bromanyl-4-methyl-naphthalen-1-yl)-4,5-dihydro-1~{H}-imidazol-2-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;2.0 M ammonium sulfate, 0.1 M sodium acetate (pH 4.6), 2 mM inhibitor
|
Resolution 1.64 Å R-free 0.188 |
| 6QSW Complement factor B protease domain in complex with the reversible inhibitor N-(2-bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine. Deposited 2019-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain CCC
474–764(291 aa)
|
Not recorded | SO4 SULFATE ION × 3 JGT ~{N}-(2-bromanyl-4-methyl-naphthalen-1-yl)-4,5-dihydro-1~{H}-imidazol-2-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;2.0 M ammonium sulfate, 0.1 M sodium acetate (pH 4.6), 2 mM inhibitor
|
Resolution 1.64 Å R-free 0.188 |
| 6QSX Complement factor B protease domain in complex with the reversible inhibitor ((2S,4S)-1-((5,7-dimethyl-1H-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)methanol. Deposited 2019-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain AAA
474–764(291 aa)
|
Not recorded | SO4 SULFATE ION × 3 JGN [(2~{S},4~{S})-1-[(5,7-dimethyl-1~{H}-indol-4-yl)methyl]-4-methoxy-piperidin-2-yl]methanol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;2.5 M ammonium sulfate, 0.1 mM sodium acetate (pH 4.6), 2 mM inhibitor
|
Resolution 1.77 Å R-free 0.220 |
| 6QSX Complement factor B protease domain in complex with the reversible inhibitor ((2S,4S)-1-((5,7-dimethyl-1H-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)methanol. Deposited 2019-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain BBB
474–764(291 aa)
|
Not recorded | SO4 SULFATE ION × 4 JGN [(2~{S},4~{S})-1-[(5,7-dimethyl-1~{H}-indol-4-yl)methyl]-4-methoxy-piperidin-2-yl]methanol × 1 ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;2.5 M ammonium sulfate, 0.1 mM sodium acetate (pH 4.6), 2 mM inhibitor
|
Resolution 1.77 Å R-free 0.220 |
| 6RAV Complement factor B protease domain in complex with the reversible inhibitor 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid Deposited 2019-04-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain AAA
474–764(291 aa)
|
Not recorded | SO4 SULFATE ION × 2 JGQ 4-[(2~{S},4~{S})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;24 % (w/v) PEG3350, 0.2 M ammonium acetate, 0.1 M Bis-Tris (pH 5.5), 2mM inhibitor
|
Resolution 1.70 Å R-free 0.227 |
| 6RAV Complement factor B protease domain in complex with the reversible inhibitor 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid Deposited 2019-04-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain BBB
474–764(291 aa)
|
Not recorded | SO4 SULFATE ION × 3 JGQ 4-[(2~{S},4~{S})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid × 1 ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;24 % (w/v) PEG3350, 0.2 M ammonium acetate, 0.1 M Bis-Tris (pH 5.5), 2mM inhibitor
|
Resolution 1.70 Å R-free 0.227 |
| 6RUR Structure of the SCIN stabilized C3bBb convertase bound to properdin Deposited 2019-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 12 PDB declaration: dodecameric |
Chain J
260–764(505 aa)
Chain L
260–764(505 aa)
|
Not recorded | MAN alpha-D-mannopyranose × 18 MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;50 mM MgAcetate 50 mM Mes 6.5 5 % w/v PEG 10K
|
Resolution 6.00 Å R-free 0.272 |
| 6RUV Structure of the SCIN stabilized C3bBb convertase bound to Properdin and a the non-inhibitory nanobody hFPNb1 Deposited 2019-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 14 PDB declaration: tetradecameric |
Chain J
260–764(505 aa)
Chain L
260–764(505 aa)
|
Not recorded | MAN alpha-D-mannopyranose × 21 MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.8;277 K;100 mM NaCl, 5 % (w/v) PEG4000, 10 mM MgCl2, 100 mM Sodium Cacodylate trihydrate pH 5.8.
|
Resolution 6.15 Å R-free 0.271 |
| 6T8U Complement factor B in complex with 5-Bromo-3-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-7-methyl-1H-indol-4-amine Deposited 2019-10-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain AAA
474–764(291 aa)
|
Not recorded | MVZ 5-bromanyl-3-chloranyl-~{N}-(1~{H}-imidazol-2-yl)-7-methyl-1~{H}-indol-4-amine × 1 SO4 SULFATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;298 K;2.4M AMMONIUM SULPHATE, 0.1 M SODIUM ACETATE PH 4.6
|
Resolution 2.84 Å R-free 0.239 |
| 6T8U Complement factor B in complex with 5-Bromo-3-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-7-methyl-1H-indol-4-amine Deposited 2019-10-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain BBB
474–764(291 aa)
|
Not recorded | MVZ 5-bromanyl-3-chloranyl-~{N}-(1~{H}-imidazol-2-yl)-7-methyl-1~{H}-indol-4-amine × 1 SO4 SULFATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;298 K;2.4M AMMONIUM SULPHATE, 0.1 M SODIUM ACETATE PH 4.6
|
Resolution 2.84 Å R-free 0.239 |
| 6T8U Complement factor B in complex with 5-Bromo-3-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-7-methyl-1H-indol-4-amine Deposited 2019-10-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain CCC
474–764(291 aa)
|
Not recorded | MVZ 5-bromanyl-3-chloranyl-~{N}-(1~{H}-imidazol-2-yl)-7-methyl-1~{H}-indol-4-amine × 1 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;298 K;2.4M AMMONIUM SULPHATE, 0.1 M SODIUM ACETATE PH 4.6
|
Resolution 2.84 Å R-free 0.239 |
| 6T8V Complement factor B in complex with (S)-5,7-Dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1H-indole Deposited 2019-10-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain AAA
474–764(291 aa)
|
Not recorded | SO4 SULFATE ION × 2 MVK 4-[(2~{S})-1-[(5,7-dimethyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;298 K;25% PEG3350, 0.1M HEPES PH 7.5, 5 mM inhibitor
|
Resolution 2.29 Å R-free 0.254 |
| 6T8V Complement factor B in complex with (S)-5,7-Dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1H-indole Deposited 2019-10-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain BBB
474–764(291 aa)
|
Not recorded | SO4 SULFATE ION × 3 MVK 4-[(2~{S})-1-[(5,7-dimethyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid × 1 ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;298 K;25% PEG3350, 0.1M HEPES PH 7.5, 5 mM inhibitor
|
Resolution 2.29 Å R-free 0.254 |
| 6T8W Complement factor B in complex with (-)-4-(1-((5,7-Dimethyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid Deposited 2019-10-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain AAA
474–764(291 aa)
|
Not recorded | SO4 SULFATE ION × 2 MVW 5,7-dimethyl-4-[[(2~{S})-2-phenylpiperidin-1-yl]methyl]-1~{H}-indole × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;298 K;25% PEG3350, 0.1M BIS-TRIS PH 6.5, 0.2M
AMMONIUM SULFATE, 0.1 MM ZNCL2, 1 mM inhibitor
|
Resolution 1.70 Å R-free 0.238 |
| 6T8W Complement factor B in complex with (-)-4-(1-((5,7-Dimethyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid Deposited 2019-10-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain BBB
474–764(291 aa)
|
Not recorded | SO4 SULFATE ION × 3 MVW 5,7-dimethyl-4-[[(2~{S})-2-phenylpiperidin-1-yl]methyl]-1~{H}-indole × 1 ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;298 K;25% PEG3350, 0.1M BIS-TRIS PH 6.5, 0.2M
AMMONIUM SULFATE, 0.1 MM ZNCL2, 1 mM inhibitor
|
Resolution 1.70 Å R-free 0.238 |
| 7JTN Human Complement Factor B Inhibited by a Slow Off-Rate Modified Aptamer of 29 Bases Deposited 2020-08-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Monomer;Protein × 1 PDB declaration: dimeric |
Chain A
1–764(764 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;0.1 M bis-tris,
0.2 M ammonium acetate,
25% peg-3350
|
Resolution 3.10 Å R-free 0.241 |
| 7JTN Human Complement Factor B Inhibited by a Slow Off-Rate Modified Aptamer of 29 Bases Deposited 2020-08-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein–DNA Monomer;Protein × 1 PDB declaration: dimeric |
Chain C
1–764(764 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;0.1 M bis-tris,
0.2 M ammonium acetate,
25% peg-3350
|
Resolution 3.10 Å R-free 0.241 |
| 7JTQ Human Complement Factor B Inhibited by a Slow Off-Rate Modified Aptamer of 31 Bases Deposited 2020-08-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Monomer;Protein × 1 PDB declaration: dimeric |
Chain A
1–764(764 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES (pH 7.5),
0.2 M ammonium acetate,
25% (w/v) peg-3350
|
Resolution 3.50 Å R-free 0.257 |
| 7JTQ Human Complement Factor B Inhibited by a Slow Off-Rate Modified Aptamer of 31 Bases Deposited 2020-08-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein–DNA Monomer;Protein × 1 PDB declaration: dimeric |
Chain C
1–764(764 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES (pH 7.5),
0.2 M ammonium acetate,
25% (w/v) peg-3350
|
Resolution 3.50 Å R-free 0.257 |
| 7NOZ Structure of the nanobody stablized properdin bound alternative pathway proconvertase C3b:FB:FP Deposited 2021-02-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 6 PDB declaration: hexameric |
Chain F
35–764(730 aa)
|
Mutation:D279G | MAN alpha-D-mannopyranose × 6 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.05 M Na-acetate pH 5.3, 0.1 M Mg-formate,7% PEG5000 MME
|
Resolution 3.90 Å R-free 0.265 |
| 8ENU Structure of the C3bB proconvertase in complex with lufaxin Deposited 2022-09-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain D
2–764(763 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.22 Å |
| 8EOK Structure of the C3bB proconvertase in complex with lufaxin and factor Xa Deposited 2022-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 6 PDB declaration: hexameric |
Chain D
2–764(763 aa)
|
Not recorded | MG MAGNESIUM ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.53 Å |
| 8UIN Structure of the C3bBb-albicin complex Deposited 2023-10-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 8 PDB declaration: octameric |
Chain J
260–487(228 aa)
Chain X
260–487(228 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4;10 mM Hepes pH 7.4, 150 mM NaCl, 5 mM MgCl2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.86 Å |
| 9U62 AP pathways C3 convertase C3bBbP and C3 complex Deposited 2025-03-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 5 PDB declaration: pentameric |
Chain B
260–764(505 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 NI NICKEL (II) ION × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.70 Å |
25 other PDB entries and 44 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | CFAB_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A; PDBConstruct 1–497; UniProt 268–764 |